Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vosoritide for Growth Deficits in MPS IVA and VI
NCT05845749Phase 2Active, not recruiting
- Sponsor
- University of California, San Francisco
- Start
- Sep 2023
- Primary completion
- Dec 2028
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vosoritide in Mucopolysaccharidosis type IV A and mucopolysaccharidosis type VI, sponsored by University of California, San Francisco. Primary endpoint: Incidence of adverse events at 48 weeks. Started Sep 2023; status: active, not recruiting.
02
Drugs
vosoritide
03
Conditions
Mucopolysaccharidosis type IV Amucopolysaccharidosis type VI
Beyond the preview
Go deeper on NCT05845749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05845749.